Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth in vivo by Suppressing the Function of NK and CD8+ T Cells

Hoos, 2016, Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations, Nat Rev Drug Discov., 15, 235, 10.1038/nrd.2015.35

Topalian, 2016, Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy, Nat Rev Cancer, 16, 275, 10.1038/nrc.2016.36

Boussiotis, 2016, Molecular and biochemical aspects of the PD-1 checkpoint pathway, N Engl J Med., 375, 1767, 10.1056/NEJMra1514296

Gopalakrishnan, 2017, Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients, Science, 359, eaan4236, 10.1126/science.aan4236

Seifert, 2017, PD-1/PD-L1 blockade enhances T-cell activity and antitumor efficacy of imatinib in gastrointestinal stromal tumors, Clin Cancer Res., 23, 454, 10.1158/1078-0432.CCR-16-1163

Ribas, 2017, Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy, Cell, 170, 1109, 10.1016/j.cell.2017.08.027

Brahmer, 2012, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, N Engl J Med., 366, 2455, 10.1056/NEJMoa1200694

Hamid, 2013, Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma, N Engl J Med., 369, 134, 10.1056/NEJMoa1305133

Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med., 366, 2443, 10.1056/NEJMoa1200690

Postow, 2015, Nivolumab and ipilimumab versus ipilimumab in untreated melanoma, N Engl J Med., 372, 2006, 10.1056/NEJMoa1414428

Wolchok, 2013, Nivolumab plus ipilimumab in advanced melanoma, N Engl J Med., 369, 122, 10.1056/NEJMoa1302369

Ansell, 2015, PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma, N Engl J Med., 372, 311, 10.1056/NEJMoa1411087

Powles, 2014, MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer, Nature, 515, 558, 10.1038/nature13904

Topalian, 2014, Balance and imbalance in the immune system: life on the edge, Immunity, 41, 682, 10.1016/j.immuni.2014.11.005

Yang, 2007, Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis, J Immunother., 30, 825, 10.1097/CJI.0b013e318156e47e

Llosa, 2015, The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints, Cancer Discov., 5, 43, 10.1158/2159-8290.CD-14-0863

Le, 2015, PD-1 Blockade in tumors with mismatch-repair deficiency, N Engl J Med., 372, 2509, 10.1056/NEJMoa1500596

Brahmer, 2010, Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates, J Clin Oncol., 28, 3167, 10.1200/JCO.2009.26.7609

Stanietsky, 2009, The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity, Proc Natl Acad Sci USA., 106, 17858, 10.1073/pnas.0903474106

Yu, 2009, The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells, Nat Immunol., 10, 48, 10.1038/ni.1674

Boles, 2009, A novel molecular interaction for the adhesion of follicular CD4 T cells to follicular DC, Eur J Immunol., 39, 695, 10.1002/eji.200839116

Linsley, 1994, Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors, Immunity, 1, 793, 10.1016/S1074-7613(94)80021-9

Levin, 2011, Vstm3 is a member of the CD28 family and an important modulator of T-cell function, Eur J Immunol., 41, 902, 10.1002/eji.201041136

Liu, 2013, Recruitment of Grb2 and SHIP1 by the ITT-like motif of TIGIT suppresses granule polarization and cytotoxicity of NK cells, Cell Death Differ., 20, 456, 10.1038/cdd.2012.141

Stanietsky, 2013, Mouse TIGIT inhibits NK-cell cytotoxicity upon interaction with PVR, Eur J Immunol., 43, 2138, 10.1002/eji.201243072

He, 2017, CD155T/TIGIT signaling regulates CD8+ T cell metabolism and promotes tumor progression in human gastric cancer, Cancer Res., 77, 6375, 10.1158/0008-5472.CAN-17-0381

Chauvin, 2015, TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients, J Clin Invest., 125, 2046, 10.1172/JCI80445

Kurtulus, 2015, TIGIT predominantly regulates the immune response via regulatory T cells, J Clin Invest., 125, 4053, 10.1172/JCI81187

Johnston, 2014, The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function, Cancer Cell, 26, 923, 10.1016/j.ccell.2014.10.018

Ahmadzadeh, 2009, Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired, Blood, 114, 1537, 10.1182/blood-2008-12-195792

Cong, 2015, Genome engineering using CRISPR-Cas9 system, Methods Mol Biol., 1239, 197, 10.1007/978-1-4939-1862-1_10

Yang, 2013, Cetuximab-mediated tumor regression depends on innate and adaptive immune responses, Mol Ther., 21, 91, 10.1038/mt.2012.184

Kohrt, 2014, Targeting CD137 enhances the efficacy of cetuximab, J Clin Invest., 124, 2668, 10.1172/JCI73014

Kim, 2007, Adaptive immune cells temper initial innate responses, Nat Med., 13, 1248, 10.1038/nm1633

Kleffel, 2015, Melanoma cell-intrinsic PD-1 receptor functions promote tumor growth, Cell, 162, 1242, 10.1016/j.cell.2015.08.052

Fridman, 2012, The immune contexture in human tumours: impact on clinical outcome, Nat Rev Cancer, 12, 298, 10.1038/nrc3245

Giannakis, 2016, Genomic correlates of immune-cell infiltrates in colorectal carcinoma, Cell Rep., 17, 1206, 10.1016/j.celrep.2016.03.075

Lal, 2015, An immunogenomic stratification of colorectal cancer: Implications for development of targeted immunotherapy, Oncoimmunology, 4, e976052, 10.4161/2162402X.2014.976052

Le, 2017, A blueprint to advance colorectal cancer immunotherapies, Cancer Immunol Res., 5, 942, 10.1158/2326-6066.CIR-17-0375

Siegel, 2014, Cancer statistics, 2014, CA Cancer J Clin., 64, 9, 10.3322/caac.21208

Marin-Acevedo, 2018, Next generation of immune checkpoint therapy in cancer: new developments and challenges, J Hematol Oncol., 11, 39, 10.1186/s13045-018-0582-8

Qiao, 2017, LIGHT elevation enhances immune eradication of colon cancer metastases, Cancer Res., 77, 1880, 10.1158/0008-5472.CAN-16-1655

Mahnke, 2016, TIGIT-CD155 interactions in melanoma: a novel co-inhibitory pathway with potential for clinical intervention, J Invest Dermatol., 136, 9, 10.1016/j.jid.2015.10.048

Inozume, 2016, Melanoma cells control antimelanoma CTL responses via interaction between TIGIT and CD155 in the effector phase, J Invest Dermatol., 136, 255, 10.1038/JID.2015.404

Manieri, 2017, TIGIT: a key inhibitor of the cancer immunity cycle, Trends Immunol., 38, 20, 10.1016/j.it.2016.10.002

Oda, 2004, Ligand stimulation of CD155α inhibits cell adhesion and enhances cell migration in fibroblasts, Biochem Biophys Res Commun., 319, 1253, 10.1016/j.bbrc.2004.05.111

Stengel, 2012, Structure of TIGIT immunoreceptor bound to poliovirus receptor reveals a cell-cell adhesion and signaling mechanism that requires cis-trans receptor clustering, Proc Natl Acad Sci USA., 109, 5399, 10.1073/pnas.1120606109

Dixon, 2018, Functional anti-TIGIT antibodies regulate development of autoimmunity and antitumor immunity, J Immunol., 200, 3000, 10.4049/jimmunol.1700407

Harjunpaa, 2018, Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis, Oncoimmunology, 7, e1445949, 10.1080/2162402X.2018.1445949